Virax Biolabs Group (Virax Biolabs Group) Accumulated other comprehensive income (loss)

: $21.13 Mil (As of Sep. 2023)

View and export this data going back to 2022. Start your Free Trial

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. Virax Biolabs Group's Accumulated other comprehensive income (loss) for the quarter that ended in Sep. 2023 was $21.13 Mil.

Virax Biolabs Group's quarterly Accumulated other comprehensive income (loss) increased from Sep. 2022 ($12.17 Mil) to Mar. 2023 ($20.92 Mil) and increased from Mar. 2023 ($20.92 Mil) to Sep. 2023 ($21.13 Mil).

Virax Biolabs Group's annual Accumulated other comprehensive income (loss) increased from Mar. 2021 ($4.03 Mil) to Mar. 2022 ($5.36 Mil) and increased from Mar. 2022 ($5.36 Mil) to Mar. 2023 ($20.92 Mil).

Virax Biolabs Group Accumulated other comprehensive income (loss) Historical Data

The historical data trend for Virax Biolabs Group's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virax Biolabs Group Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Accumulated other comprehensive income (loss)

2.92

4.03

5.36

20.92

Virax Biolabs Group Semi-Annual Data
	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Accumulated other comprehensive income (loss)				4.44	5.36	12.17	20.92	21.13

Virax Biolabs Group Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

Virax Biolabs Group Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of Virax Biolabs Group's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Virax Biolabs Group (Virax Biolabs Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » Accumulated other comprehensive income (loss)

Comparable Companies

Traded in Other Exchanges

N/A

Address

20 North Audley Street, London, GBR, W1K 6LX

Website

https://www.viraxbiolabs.com

Virax Biolabs Group Ltd is a innovative biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.